| Phase 16 trials |
|
Phase 1
|
NCT05349890 |
Apr 2023 → Apr 2027 expected |
epithelial neoplasm |
Providence Health & Services |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04616248 |
Jan 2023 → Jan 2027 expected |
basal cell carcinoma, bone sarcoma, breast carcinoma, cutaneous neuroendocrine carcinoma +3 |
University of Southern California |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05484011 |
Dec 2022 → Mar 2024 |
pancreatic adenocarcinoma |
HiberCell, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT05029999 |
Apr 2022 → Apr 2028 expected |
Her2-receptor negative breast cancer |
University of Texas Southwestern Medical Center |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04520711 |
Feb 2022 → Dec 2026 expected |
epithelial neoplasm |
Providence Health & Services |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT03329950 |
Dec 2017 → Sep 2022 |
MALT lymphoma, Waldenstrom macroglobulinemia, breast cancer, cholangiocarcinoma +16 |
Celldex Therapeutics |
Completed
|
No outcome recorded
|
| Phase 1/23 trials |
|
Phase 1/2
|
NCT05849480 |
May 2024 → Jun 2040 expected |
bile duct cancer |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04491084 |
Jan 2021 → Aug 2022 |
non-small cell lung carcinoma |
Albert Einstein College of Medicine |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT04364230 |
Sep 2020 → Mar 2024 |
uveal melanoma |
Craig L Slingluff, Jr |
Completed
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT06980038 |
May 2026 → Nov 2027 expected |
hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, nasal cavity squamous cell carcinoma, nasopharyngeal carcinoma +2 |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05231122 |
Mar 2024 → Mar 2027 expected |
endometrial serous adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, ovarian clear cell adenocarcinoma +3 |
Roswell Park Cancer Institute |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04536077 |
Aug 2021 → Nov 2023 |
malignant pancreatic neoplasm |
Washington University School of Medicine |
Terminated
|
No outcome recorded
|